In mouse models of melanoma adding check point inhibitors to intralesional (IL) PV-10 improved tumour regression and stimulated immune response, reports a study presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting, 6-9 November, National Harbor, Maryland, USA¹.
MRV Research
New PD-1 immune checkpoint inhibitor Opdivo (nivolumab) first to demonstrate survival benefit in Phase 3 trial in treatment naïve advanced melanoma
Results of a Phase 3 randomized double-blind study conducted in Canada, Australia and Europe show that Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor from Bristol-Myers Squibb Company, demonstrated superior overall survival compared to the chemotherapy dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type advanced melanoma (n=418
Treatments Show Promise in Metastatic Melanoma
In metastatic melanoma, nivolumab improves overall and progression-free survival versus dacarbazine, and dabrafenib plus trametinib improves survival versus vemurafenib monotherapy, according to two studies published online Nov. 16 in the New England Journal of Medicine.
Genes and Sun Behaviors During Childhood May Play Large Role in Future Melanoma Risk
A longitudinal study established a link between different ultraviolet (UV) exposure measures in children, such as the number of waterside vacations or sunburns, and biomarkers of melanoma risk, such as the number of freckles or moles that develop during childhood, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.Neil Box, PhD